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Abstract
Background: It is known that the vast majority of prostate cancers are multifocal. However radical radiotherapy
historically treats the whole gland rather than individual cancer foci.
Magnetic resonance spectroscopy (MRS) can be used to non-invasively locate individual cancerous tumours in
prostate. Thus an intentionally non-uniform dose distribution treating the dominant intraprostatic lesion to different
dose levels than the remaining prostate can be delivered ensuring the maximum achievable tumour control
probability.
The aim of this study is to evaluate, using radiobiological means, the feasibility of a MRS-guided high dose rate
(HDR) brachytherapy boost to the dominant lesion.
Methods: Computed tomography and MR/MRS were performed for treatment planning of a high risk localised
prostate cancer. Both were done without endorectal coil, which distorts shape of prostate during the exams.
Three treatment plans were compared:
- external beam radiation therapy (EBRT) only
- combination of EBRT and HDR brachytherapy
- combination of EBRT and HDR brachytherapy with a synchronous integrated boost to the dominant lesion
The criteria of plan comparison were: the minimum, maximum and average doses to the targets and organs at risk;
dose volume histograms; biologically effective doses for organs at risk and tumour control probability for the target
volumes consisting of the dominant lesion as detected by MR/MRS and the remaining prostate volume.
Results: Inclusion of MRS information on the location of dominant lesion allows a safe increase of the dose to the
dominant lesion while dose to the remaining target can be even substantially decreased keeping the same, high
tumour control probability. At the same time an improved urethra sparing was achieved comparing to the
treatment plan using a combination of EBRT and uniform HDR brachytherapy.
Conclusions: MRS-guided HDR brachytherapy boost to dominant lesion has the potential to spare the normal
tissue, especially urethra, while keeping the tumour control probability high.
Background
It is known that the vast majority of prostate cancers are
multifocal. However radical radiotherapy historically
treats the whole gland rather than eradicate individual
cancer foci and true optimization of dose distributions
in prostate cancer is not performed due to uncertainties
in the position of dominant intraprostatic lesion (DIL)
within the prostate. Provided the areas of tumour bur-
den can be localized within the prostatic volume, an
intentionally non-uniform dose distribution treating the
dominant intraprostatic lesion (DIL) and the remaining
prostate to a dose ensuring the maximum achievable
tumour control probability (TCP) can be delivered.
The magnetic resonance spectroscopy (MRS) can be
used non-invasively to diagnose and locate cancerous
tumours in the prostate [1]. The majority of MRS inves-
tigations of prostate cancer employ proton MRS (1 H
MRS) with molecules studied including choline, citrate,
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lactate and creatine, as well as water and lipids. Areas
significantly infiltrated by prostate adenocarcinoma have
higher choline to citrate ratio on MRS investigation
compared to normal prostatic tissue and benign hyper-
trophy [1,2].
There are a number of studies supporting the value of
MRS for prostate cancer diagnosis and treatment plan-
ning. Studies of MRS to direct prostate biopsy show
that the use of combination MRI and MRS may reduce
the rate of false-negative biopsies and hence decrease
the need for more extensive biopsy protocols and/or
repeated biopsy procedures [3]. The combination of
volumetric data from MRS and anatomical display of
MR improves the evaluation of extracapsular extension
(ECE) [4]. MRS can diagnose metabolic atrophy which
is indicative of successful treatment because the growth
of normal or abnormal cells cannot occur without meta-
bolism. Thus MRS also has the potential to be an earlier
indicator for resolution of local disease than the PSA
nadir [5,6]. The ratio of (choline + creatine)/citrate from
MRS examination was also found to correlate with the
Gleason grade from biopsy, which in most cases corre-
lates to the aggressiveness of prostate cancer [7].
A number of studies investigated the feasibility of
including MRSI data into radiotherapy treatment plan-
ning for prostate cancer [8-12]. These studies show that
the radiotherapy planning of intensity modulated radio-
therapy (IMRT) as well as low dose rate (LDR) bra-
chytherapy to boost the dose to MRS-defined regions is
technically feasible with both of these treatment
techniques.
The aim of this study is to evaluate the feasibility and
the impact of a MRS-guided high dose rate (HDR) bra-
chytherapy boost to the DIL in prostate cancer by com-
paring the radiobiological outcome of different
treatment modalities in a case study of a prostate cancer
patient.
Methods
Study
A planning study of dose escalation to a MRS-defined
dominant lesion with a combination of external beam
therapy and the HDR brachytherapy was performed.
This study is part of our broader research project inves-
tigating the use of MRS in prostate radiotherapy. The
project has been granted ethics approval by the Towns-
ville Hospital Ethics Committee for the additional MR/
MRS investigation and use of images. Patient informed
consent was obtained.
Patient
A patient with a high risk localised prostate cancer, no
history of prior radiotherapy and no evidence of distant
metastatic disease, was chosen for this study.
The volume of prostate was 63cm3. Six specimens of
tissue were obtained with transrectal ultrasound sextant
(TRUS) biopsy, which was the standard approach at the
Townsville Hospital at the time of this study. Each
biopsy specimen consisted of thin fragments of tissue
measuring 12-18 mm in length. The biopsy revealed
adenocarcinoma of the prostate in the three cores on
the right side and none in the three cores on the left
side of the prostate, with 100%, 70% and 30% of core
involvement in the right superior, mid and inferior
cores, respectively. Gleason score was 3+4 = 7 for all
the cancer-positive cores. The prostate specific antigen
(PSA) at diagnosis was 5.3 ng/ml and the clinical stage
from digital rectal examination and the MRI was T3a
according to AJCC-TNM [13].
Imaging
In addition to the conventional computed tomography
(CT) for treatment planning, a combined MR/MRS
examination was performed. The patient was scanned
with bowel and bladder preparation during both CT and
MR/MRS acquisitions to improve reproducibility
according to the following protocol:
- Bladder and rectal volume should not vary between
simulation CT, MRI and treatments
- Bladder should be emptied “twice” one hour prior
to scan/treatment, patient should drink two glasses
of water soon thereafter
- Fibogel should be started one week before planning
and one week before treatment
Consider administering glycerine suppositories 30 min
prior to scan and treatment unless bowel movement
(less than 1 hour before)
The CT and MRI scans were performed using the
same immobilization system applied to radiotherapy
planning, including head rest, knee support and feet
rest.
MR images were obtained with a 1.5T clinical scanner
(Magnetom Symphony, Siemens, Erlangen, Germany),
without contrast. To minimise examination time and
improve patient’s compliance only the following MR
sequences were performed: For the morphological study,
T2-weighted (T2W) turbo spin echo (TSE) images with
high spatial resolution, 3 mm slice thickness with no
gap between slices, were acquired in the transversal
plane including the entire prostate and seminal vesicles;
A three plane T2W study was conducted, including the
T2W true fast imaging with steady-state precession
(FISP) axial, coronal and sagittal. A belt was placed over
the phase array coil to reduce the effect of motion.
The magnetic resonance spectroscopic imaging used
the point resolved spatially localized spectroscopic
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sequence (PRESS) with fat and water spectral suppres-
sion and TE/TR = 135/1500. Magnetic field homogeneity
in the volume of interest was ensured by manual shim-
ming the water resonance peak. We have found that
when using the 1.5T scanner and no endorectal coil, the
manual shimming was crucial to obtaining spectra with
acceptable signal-to-noise ratio.
Shimming for two-dimensional (2D) MRSI was found
to be easier and faster than for three-dimensional (3D)
MRSI, as it was carried out only for the thickness of one
slice. A body coil positioned directly above the prostate
and one of the spine coils directly below prostate
volume, were used instead of an endorectal (ER) coil for
the MR signal reception. The total MR/MRS session
was approximately 45 minutes long.
Positioning of the MRS volume of interest (VOI) in
the superior-inferior direction was guided by the under-
lying 3D axial T2 morphological images, in order to
include the level suspected to contain the dominant
intraprostatic lesion. The VOI was adjusted to comple-
tely cover the prostate on the selected transverse slice,
with an additional row of voxels around the prostate.
The voxel size was 10x10x10 mm3. With further optimi-
sation of our MRS technique we were able to decrease
the voxel size to 7x7x7mm3 while keeping a similar sig-
nal to noise ratio. However all patients scanned using
the smaller voxel size had multiple dominant lesions in
the prostate, thus could not be used for this study as
the dose escalation to the dominant lesions would not
be practical.
Positioning of the 2D MRS slice in the inferior-poster-
ior and lateral directions was critical to obtain a mini-
mum overlap of different tissue types within each voxel.
The dominant intraprostatic lesion (DIL) was located
on the co registered MR/MRS as the region of hypoin-
tensity and was confirmed by MRS to be an aggressive
cancer. The DIL was subsequently delineated according
to this region of hypointensity on MRI, as MRS didn’t
have sufficient resolution for accurate delineation, even
if the smaller voxel size of 7x7x7mm3 was used. The
resolution of MRS could be improved if the voxel size
was decreased; however it would also mean decreasing
the MRS signal strength. Further progress in signal
acquisition and technology is necessary to improve the
signal-to-noise ratio, thus allowing a smaller MRS voxel
size.
Treatment planning
CT and MR images were transferred to the CMS XiO
treatment planning system for external beam treatment
planning. MR images were also transferred to the Nucle-
tron Plato treatment planning system for high dose rate
(HDR) brachytherapy planning, as the DIL could be pre-
cisely localized on the MR images. Normal structures
delineated on CT images were left and right femoral
head and necks, rectum and patient outline, normal
structures delineated on the MRI: urethra and rectum.
The definitions of clinical and planning target volumes
are summarized in Table 1.
Three treatment plans were prepared:
Plan A
- external beam radiation therapy (EBRT) combined
with androgen deprivation therapy (ADT) starting
6months prior to the start of EBRT and continuing
for two years after completion of EBRT
- conformal plan utilizing five 10MV photon beams
at gantry angles of 0°, 54°, 83°, 253° and 282°
- prescription dose: 74 Gy delivered in 37 fractions
- for the PTVEBRT: V95 to be equal 100%; however
in this case, due to rectum DVH being close to tol-
erance and the particular rectal filling, the radiation
oncologist accepted the plan with V95 of 98% for
the PTVEBRT
Plan B
- combination of EBRT and HDR brachytherapy
- EBRT plan delivering 60Gy to PTVEBRT in
30fractions
- HDR brachytherapy delivering 10Gy to the
PTVHDR in one fraction
Plan C
- combination of EBRT and HDR brachytherapy
with a synchronous integrated boost (SIB)
- EBRT plan delivering 60Gy to PTVEBRT in 30frac-
tions to prostate
- HDR brachytherapy delivering one dose level to
the PTVHDR and a boost to the PTVDIL in one frac-
tion, where dose levels are optimized to maximise
the TCP and at the same time, minimise the doses
to the critical normal organs; these final optimized
dose levels were 7.5Gy for the PTVHDR and a conco-
mitant boost of 7.5Gy to the PTVDIL
Table 1 Target volumes definition
CTVCT = prostate gland + base of seminal vesicles, delineated on CT
CTVMR = prostate gland only, delineated on MRI
CTVDIL = dominant intraprostatic nodule, delineated on MRI/MRSI
PTVEBRT = CTVCT + 10 mm margin in all directions but posteriorly where
5 mm where used
PTVHDR = CTVMR
PTVDIL = CTVDIL
“CTV” is the clinical target volume, “PTV” - the planning target volume,
subscript “EBRT” refers to the external beam radiotherapy, “HDR” - to the high
dose rate brachytherapy, “DIL” - the dominant intraprostatic lesion.
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The plan ‘A’ dose constrains for organs at risk were as
follows:
- rectum: less then 4% of volume should receive
more then 74Gy; less than 20% - 70Gy; less than
30% - 60Gy and less than 70% - 30Gy.
- femoral head and necks: less then 60% of volume
should receive more then 40Gy and less then 40% of
volume - more then 60Gy.
These dose constrains were derived from the results of
a consensus process on the Australia and New Zealand
radiotherapy standards, initiated by the Faculty of Radia-
tion Oncology Genito-Urinary Group [14]. Dose of
more than 70Gy was prescribed to at least 99% of
PTVEBRT. For the EBRT part of plans ‘B’ and ‘C’ only 30
fractions of this plan were planned to be delivered.
During HDR brachytherapy planning, care was taken
for the 100% prescription dose to fully encompass the
PTVHDR, and additionally for the second brachytherapy
plan, for the 15Gy isodose to fully encompass the
PTVDIL. A maximum of 15Gy delivered to the urethra
was accepted and the dose to the rectum was minimised
as long the target coverage was not compromised.
Treatment plan evaluation
The plans were compared in terms of minimum, maxi-
mum and average doses to the targets and organs at
risk, the dose volume histograms as well as biologically
effective doses for organs at risk and tumour control
probability (TCP) for the target volumes.
Radiobiological modelling was used to compute and
compare the TCP for a range of tumour sensitivity for
all three plans. Calculation of TCP was based on the lin-
ear-quadratic (LQ) model including repopulation
according to the Equation 1, where SF is the surviving
fraction, D - the total dose, and d - dose per fraction, a-
the initial slope of a cell survival curve, b- the curvature
of the cell survival curve, ttreatment - time of the treat-
ment, Trepop - doubling time (equal to 42days).
SF D nd t
Trepop
treatment= − − − ⋅
⎡
⎣
⎢⎢
⎤
⎦
⎥⎥exp
ln  2 2 (1)
For combined treatment modalities of external therapy
and brachytherapy, the combined clonogen survival S
can be calculated according to the Equation 2:
S S SEBRT HDR= ⋅ (2)
TCP was calculated according to the Equation 3,
where N0 is the initial number of cancer clonogens.
TCP N S= −exp( )0 (3)
There was much discussion following the clinical evi-
dence supporting the idea that the prostate tumours
have exceptionally low a/b values [15]. Therefore we
have employed two sets of radiobiological data for the
prostate cancer. One dataset assumes the a/b =1.5Gy,
a =0.0391Gy-1 and the number of clonogens N0 =290
[16]. A second dataset assumes the a/b =3.1Gy,
a =0.15Gy-1 and N0 =10
6-107 [17]. These two a/b
ratios, as pointed out by Fowler [18], differ in the
assumption of the time of onset of the repopulation,
which is late for the a/b =1.5Gy and early (of 0 or 28
days after starting the treatment) for the a/b =3.1Gy.
Thus here the repopulation for the a/b =1.5Gy dataset
was not taken into account, and was assumed to start at
the beginning of treatment for the a/b =3.1Gy dataset.
Additionally, a ratio of clonogens in the DIL to rest of
prostate was assumed to be 90:10 [19].
For combination of modalities and different fractio-
nation schemes, the dose has to be recalculated to the
BED dose, corresponding to a 2Gy radiation fraction.
The linear quadratic model can be used to calculate
the biologically effective dose (BED) according to
Equation 4. The a/b ratio for normal tissues was
assumed to be 3.
BED D
d
= +
⎛
⎝⎜
⎞
⎠⎟1  / (4)
Results
MRSI
The MRSI results are show on figure 1. On the upper
picture all single voxels included in the volume selected
in the spectroscopic sequences are graphically repre-
sented in a two-dimensional (2D) image as a grid over-
lying the corresponding T2-weighted transverse image,
along with a color map corresponding to the choline/
citrate ratio. On the lower picture, the MRS spectra for
respective voxels are presented. Due to the thickness of
the MRS slice (10mm) and MR axial slice (3mm), the
MRS slice covered three MR slices. Therefore, the mid-
dle one of the three slices was selected for overlaying
the MRS grid for evaluation. Voxels on the right side of
prostate, in the region of suspected dominant lesion,
show elevated levels of choline, the marker of active
tumour growth.
Figure 2 shows the underlying MRI image for
comparison.
Kazi et al. BMC Cancer 2010, 10:472
http://www.biomedcentral.com/1471-2407/10/472
Page 4 of 10
External beam plans
Figure 3A shows the dose distribution and figure 4A -
the dose volume histograms (DVHs) for the conformal
external beam plans where the dose is relative to the
PTVEBRT prescription dose. DVHs shown are for
PTVEBRT, rectum, right femoral head and neck and left
femoral head and neck. The PTVEBRT volume wraps
around the rectum on the right side, making it a very
difficult treatment case for the external conformal beam
therapy planning. The doses to the femoral head and
necks as well as the rectum were pushed towards the
tolerances of these organs to achieve good coverage of
PTVEBRT and for a realistic comparison of TCP values
between the different radiotherapy delivery methods.
The results are shown in table 2.
The resulting TCP was 76.4% with TCP of 78.8% for
the DIL and 97.0% for the rest of PTVEBRT, calculated
for the a/b ratio of 1.5. The TCP vales for both for a/b
ratio of 1.5 and 3.1 are presented on Figure 4.
HDR brachytherapy plans
The HDR brachytherapy plan delivering 10Gy to whole
PTVHDR resulted in TCP values of 99.7% and 99.8% for
a/b ratio of 1.5 and 3.1, respectively.
In the SIB HDR brachytherapy plan dose levels were
optimized to match the TCP of the 10Gy HDR bra-
chytherapy plan for the PTVDIL and remaining PTVHDR.
As for the standard brachytherapy plan the TCP was
close to 100%, it was found that to achieve the same
level of tumour control, doses of just 7.5Gy to PTVHDR
and an additional 7.5Gy boost to the PTVDIL were
needed.
Figures 3B and 3C show the dose distribution for the
HDR brachytherapy plans delivering 10Gy to the
PTVHDR and the SIB HDR plan, respectively.
Figure 4B shows the dose volume histograms for the
HDR brachytherapy plans delivering 10Gy to the
PTVHDR (dashed lines) and the SIB HDR plan delivering
7.5Gy to the PTVHDR and a concomitant boost of 7.5Gy
to the PTVDIL (continuous lines). The DVHs for the
PTVDIL, PTVHDR excluding PTVDIL, rectum and urethra
are shown. The HDR brachytherapy plan delivering
10Gy to the PTVHDR used 12 needles, while the SIB
HDR brachytherapy plan used 14 needles.
The minimum, maximum and average doses to rec-
tum, bladder, PTVHDR excluding PTVDIL, PTVDIL and
Figure 1 Up: T2-weighted transverse MR image, with the MRSI
grid and a color map corresponding to the choline/citrate
ratio. Down: MRS spectra for respective voxels.
Figure 2 Underlying MR image to the MRS spectra presented
on figure 1A.
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urethra; as well as volume irradiated to 90, 100, 125, 150
and 200% of prescription dose (V90, V100, V125, V150
and V200, respectively), dose to the 100% and 90% of
volume (D100 and D90, respectively) for PTVHDR
excluding PTVDIL, PTVDIL and urethra are shown in
table 3. The prescription dose for PTVHDR, PTVDIL and
urethra for 10Gy HDR brachytherapy plan was
considered to be 10Gy; for the SIB HDR brachytherapy
plan the prescription dose to PTVHDR excluding PTVDIL
and urethra was 7.5Gy and 15Gy for the PTVDIL.
Table 4 shows the minimum, maximum and average
biologically equivalent doses (BED) to organs at risk
for all investigated treatment plans. As can be con-
cluded from table 4 and shown on figure 4, the two
urethra DVH curves for the two HDR brachytherapy
plans are well separated. The SIB HDR brachytherapy
plan allowed a substantial shift in the urethra DVH
towards lower doses, potentially improving urethra
sparing.
Discussion
Brachytherapy is one of the techniques capable of deli-
vering intentionally inhomogeneous dose distributions
to the target volume. Thus it is possible to adopt an
approach presented here, where a higher dose, pre-
scribed according to the required tumour control prob-
ability derived from radiobiological models, is delivered
to the tumour burden and a homogenous dose to the
whole prostate while the dose to surrounding normal
organs can be maintained or even minimised. A number
of studies investigated the feasibility of including MRS
data into brachytherapy plans with prostate implants
[8,9,20]. These studies found that it is theoretically pos-
sible to achieve tumour dose escalation in MRS-identi-
fied intraprostatic tumour deposits without concomitant
delivery of escalated doses to the urethra.
To our knowledge this is the first study comparing
radiotherapy plans for conventional EBRT, combination
of EBRT and HDR brachytherapy and MRS-guided SIB.
We have investigated the potential impact of adding the
MRS data to the HDR brachytherapy planning, where
the dose prescription can be further customised to be
more patient-specific.
Our study is also unique as both CT/MR were per-
formed without ER coil, which distorts the shape of
prostate during the MR/MRS investigation. Thus this
study doesn’t require image transformation. Although
the majority of prostate MRS to date is performed using
ER coil, the use of external surface coils for both 2D
and 3D MRS of prostate cancer was found to be feasible
[21]. Our experience at the Townsville Cancer Centre
also confirms that prostate MRSI with a combination of
multiple external coils is feasible with diagnostic signal-
to-noise ratios.
We have shown that the dose to the DIL can be safely
increased while the dose to the remaining PTV can be
even substantially decreased keeping the same, high
tumour control probability and decreasing the doses to
critical normal organs, when compared to the uniform
HDR brachytherapy plan. Normal tissue sparing is espe-
cially important in case of HDR brachytherapy, where
Figure 3 Dose distributions for the following plans: conformal
external beam plans where dose is relative to the prescription
dose to the target (A); the HDR brachytherapy plan where the
100% isodose corresponds to 10Gy (B) and the SIB HDR
brachytherapy plan where the 100% isodose corresponds to
7.5Gy (C).
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Figure 4 Dose volume histograms (DVHs) for the conformal external beam plans where dose is relative to the prescription dose to
the target (A), and for the HDR brachytherapy plans (B) delivering 10Gy to the whole prostate (dashed lines) and the SIB HDR
brachytherapy plan (continuous lines). Table on Figure B. shows TCP values for the investigated treatment plans.
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the fraction size is larger then for the EBRT and there-
fore the BED, which is connected to the clinical effect,
is larger than the same dose delivered in standard EBRT
fractionation scheme.
As the total radiation dose is not a reliable measure of
biological effect when dose per fraction or dose rate is
changed, the concept of biologically effective dose (BED)
was used to compare doses to normal tissues. BED can
be calculated for any dose per fraction if a value of a/b
for the appropriate tissue is assumed. The a/b ratio
determines the sensitivity of a particular cell type to
alterations in radiation fraction size [22]. The effects of
BED on freedom from PSA failure at 10years and post-
treatment biopsy demonstrate a strong dose-response
relationship [23].
In HDR brachytherapy the dose delivered to urethra is
one of the main concerns. The risk of urethral stricture
treatment after prostate cancer therapy is considerable
at 1.1 to 8.4%, being highest after brachytherapy plus
external beam radiotherapy or radical prostatectomy,
with a delayed onset after radiation treatment [24].
Inclusion of MRS information on the location of the
DIL allowed us to develop a radiotherapy plan with an
improved urethra sparing while keeping the tumour
control probability high. In other patients the degree of
normal tissue sparing can vary, depending on the num-
ber and size of the dominant lesions as well as their
location, mainly the proximity to the urethra and
rectum.
T3a patient is not the ideal candidate for focal therapy
[25]. However in this case we were able to reliably
establish the location of the lesion within prostate and
the prostatic volume outside of the DIL still received
dose of 60Gy of the EBRT and 7.5Gy of the HDR bra-
chytherapy for the SIB plan.
In a certain group of patients, where multiple DILs are
present, the delivery of a boost dose to the dominant
lesions can be impractical. Performing MRS was impor-
tant to establish that a second potentially important
lesion does not exist as it could preclude delivery of the
boost dose. Thus MRS was not only confirming the
results of biopsy and MRI. Another approach would be
to increase the number of biopsy samples, however
MRS has the advantage of being an non-invasive
procedure.
Also due to some of the technical limitations of MRS
the advantages of selective boost to the DIL in prostate
cancer may not be fully utilised. Although the resolution
of MRS is constantly improving, it is still inferior to the
resolution of such imaging techniques as MRI. Due to
the MRS voxel size very small lesions may be missed. In
our study MRSI was not used to fully analyse the size
and shape of the DIL, but to confirm the location of the
tumour burden, therefore the voxel size was not crucial.
The success of treatment employing the selective boost
to the dominant lesion could be monitored with regular
PSA tests. Follow-up MRS to detect any remaining cho-
line levels could also be performed; however we are not
aware of studies investigating the optimal timing of pros-
tate MRS for radiotherapy follow-up. Repeated MRS
Table 2 Dose-volume parameters for the PTVEBRT and
CTVCT for the 74Gy external beam plan
PTVEBRT CTVCT
V90 1.00 1.00
V95 0.98 1.00
V100 0.18 0.32
V125 0.00 0.00
D100, Gy 69.60 72.00
D90, Gy 71.70 73.00
Dmin, Gy 67.42 71.06
Dmax, Gy 74.43 74.45
Dav, Gy 73.04 73.69
V90, V95, V100 and V125 are volumes irradiated to 90, 95, 100 and 125% of
prescription dose of 74Gy, respectively. D100 and D90 are doses to the 100%
and 90% of volume, respectively.
Table 3 Dose parameters for investigated HDR brachytherapy plans
PTVHDR - PTVDIL PTVDIL urethra
10Gy HDR
brachytherapy
SIB HDR
brachytherapy
10Gy HDR
brachytherapy
SIB HDR
brachytherapy
10Gy HDR
brachytherapy
SIB HDR
brachytherapy
V90 1.00 1.00 1.00 1.00 0.98 0.99
V100 1.00 1.00 1.00 1.00 0.90 0.90
V125 0.85 0.86 0.94 0.88 0.34 0.35
V150 0.50 0.54 0.71 0.60 0.00 0.00
V200 0.17 0.27 0.24 0.34 0.00 0.00
D100, Gy 9.75 7.50 11.00 15.75 8.75 6.56
D90, Gy 12.00 9.00 13.00 18.38 10.00 7.50
Dmin, Gy 9.37 7.13 10.77 15.08 8.41 6.36
Dmax, Gy 363.09 240.99 83.20 124.70 14.32 10.74
Dav, Gy 17.92 14.90 18.84 29.76 11.57 8.72
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investigations could be done, however such an approach
would not be cost-efficient. Another option would be
performing MRS when indicated by increasing PSA. The
saturation biopsy could also be employed in this case.
However in this case even if a recurrence of tumour in
another location within the prostate was detected,
retreatment would be difficult because of the doses
already delivered outside of the DIL.
Conclusions
MRS-guided HDR brachytherapy boost to DIL has the
potential to spare the normal tissue, especially urethra,
while keeping the tumour control probability high.
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